Biomx Inc
PHGE1.930USD
-0.070-3.50%
收盤 12/26, 16:00（美東）報價延遲15分鐘
2.72M總市值
虧損本益比TTM
關於 Biomx Inc 公司
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Biomx Inc簡介
公司代碼PHGE
公司名稱Biomx Inc
上市日期Dec 18, 2018
CEOSolomon (Jonathan Eitan)
員工數量52
證券類型Ordinary Share
年結日Dec 18
公司地址22 Einstein St.
城市NESS-ZIONA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家Israel
郵編7414003
電話972723942377
網址https://www.biomx.com/
公司代碼PHGE
上市日期Dec 18, 2018
CEOSolomon (Jonathan Eitan)
Biomx Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-0.03%
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
--
--
Dr. Russell G. Greig, Ph.D.
Dr. Russell G. Greig, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Eddie Williams
Mr. Eddie Williams
Independent Director
Independent Director
--
--
Mr. Gregory Merril
Mr. Gregory Merril
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-0.03%
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月18日 週二
更新時間: 11月18日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
其他
65.03%
持股股東
持股股東
佔比
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
其他
65.03%
股東類型
持股股東
佔比
Hedge Fund
26.70%
Corporation
12.29%
Holding Company
3.69%
Venture Capital
3.36%
Research Firm
1.49%
Individual Investor
1.33%
Investment Advisor/Hedge Fund
0.36%
Investment Advisor
0.09%
其他
50.69%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
38
10.55M
39.72%
-5.15M
2025Q2
48
19.36M
73.97%
+6.20M
2025Q1
47
17.95M
68.92%
+5.32M
2024Q4
47
13.90M
76.65%
+2.77M
2024Q3
43
13.00M
74.85%
+8.58M
2024Q2
33
4.45M
66.70%
+1.05M
2024Q1
34
2.97M
56.90%
+586.97K
2023Q4
35
2.25M
51.72%
+502.58K
2023Q3
39
1.91M
46.61%
-56.19K
2023Q2
39
1.94M
47.21%
+273.60K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Deerfield Management Company, L.P.
2.49M
9.39%
--
--
Jun 30, 2025
Cystic Fibrosis Foundation
2.49M
9.39%
+706.35K
+39.51%
Feb 27, 2025
Nantahala Capital Management, LLC
2.49M
9.39%
--
--
Jun 30, 2025
Centaurus Investments Limited
1.07M
4.03%
+1.07M
--
Apr 21, 2025
AMR Action Fund LP
876.89K
3.3%
+571.40K
+187.05%
Sep 30, 2024
Telmina Ltd
560.27K
2.11%
+276.30K
+97.30%
Sep 30, 2024
Nimble Ventures LLC
510.20K
1.92%
+1.00
+0.00%
Sep 30, 2024
J.P. Morgan Securities LLC
430.00K
1.62%
--
--
Jun 30, 2025
Dafna Capital Management, LLC
401.14K
1.51%
--
--
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
公告日期
類型
比率
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
常見問題
Biomx Inc的前五大股東是誰？
Biomx Inc的前五大股東如下：
Deerfield Management Company, L.P.持有股份：2.49M佔總股份比例：9.39%。
Cystic Fibrosis Foundation持有股份：2.49M佔總股份比例：9.39%。
Nantahala Capital Management, LLC持有股份：2.49M佔總股份比例：9.39%。
Centaurus Investments Limited持有股份：1.07M佔總股份比例：4.03%。
AMR Action Fund LP持有股份：876.89K佔總股份比例：3.30%。
Deerfield Management Company, L.P.持有股份：2.49M佔總股份比例：9.39%。
Cystic Fibrosis Foundation持有股份：2.49M佔總股份比例：9.39%。
Nantahala Capital Management, LLC持有股份：2.49M佔總股份比例：9.39%。
Centaurus Investments Limited持有股份：1.07M佔總股份比例：4.03%。
AMR Action Fund LP持有股份：876.89K佔總股份比例：3.30%。
Biomx Inc的前三大股東類型是什麼？
Biomx Inc 的前三大股東類型分別是：
Deerfield Management Company, L.P.
Cystic Fibrosis Foundation
Nantahala Capital Management, LLC
Deerfield Management Company, L.P.
Cystic Fibrosis Foundation
Nantahala Capital Management, LLC
有多少機構持有Biomx Inc(PHGE)的股份？
截至2025Q3，共有38家機構持有Biomx Inc的股份，合計持有的股份價值約為10.55M，占公司總股份的39.72% 。與2025Q2相比，機構持股有所增加，增幅為-34.24%。
哪個業務部門對Biomx Inc的收入貢獻最大？
在--，--業務部門對Biomx Inc的收入貢獻最大，創收--，占總收入的--% 。
